Abstract
Objective To compare the effect and safety of lamivudine (LAM) with adefovir (ADV) combined treatment and entecavir monotherapy (ETV) in hepatitis B recurrence patients. Methods A total of 60 chronic hepatitis B recurrence outpatients and inpatients in First People's Hospital of Xiaoshan District and Affiliated Hospital of Hangzhou Normal University were enrolled. Sixty patients were divided into LAM+ADV group (30 cases) and ETV group (30 cases) . The indicators of response and breakthrough rates of virology, negative and sero-conversion rates of HBeAg/HBsAg, as well as hepatic function and renal function were detected after 96-week treatment. Results The virological response rate, HBeAg negative conversion rate and sero-conversion rate of LAM+ADV group were 92.00%, 44.00% and 40.00%, and were all higher than ETV group by week 96 (χ2=0.048, 0.047, 0.041, P all 0.05) . Serum creatinine had no statistical difference in both two groups after 96-week treatment (P>0.05) . Conclusions The indicators of sustained virological response, HBeAg negative conversion and HBeAg sero-conversion rate in patients with LAM and ADV combined therapy are superior to ETV monotherapy, and have renal safety. Key words: Hepatitis B, chronic; Relapse; Lamivudine; Adefovir; Entecavir
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
